Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam and Mayo Clinic Partner to Develop RNAi Parkinson s Drug

NEW YORK, Oct. 30 - Alnylam, of Cambridge, Mass., has formed a collaboration with researchers at the Mayo Clinic in Rochester, Minn., to develop an RNA interference-based drug that suppresses genes over-expressed in people with Parkinson's disease, the company said today.


Under the collaboration, Alnylam will define and synthesize RNA interference -  or RNAi -- compounds, and will provide them to the Mayo Clinic researchers, which have recently identified a causal pathway in Parkinson's disease and published these findings in Science.  Alnylam will also fund research at the Mayo Clinic for development of the drug that expresses a gene in the pathway, alpha-synuclein, the company said. The Mayo Clinic researchers will test the RNAi compounds and test them for in vitro and in vivo efficacy.


"This collaboration with Alnylam creates the possibility of previously unimagined therapeutic advances for Parkinson's patients," Matthew Farrer, assistant professor of neuroscience and the director of a neurogenetics laboratory at Mayo Clinic in Jacksonville, Fla., said in a statement.


The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.